Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
Catheter Precision, Inc. (NYSE American:VTAK) has announced a new publication in the October 2024 issue of HeartRhythm Case Reports, highlighting the use of their VIVO technology in a novel, non-invasive ablation technique called stereotactic radioablation (STAR). The procedure, which uses external photon beams to target and ablate areas of the heart responsible for arrhythmia, demonstrated success in a patient unresponsive to traditional ablation for ventricular tachycardia.
Key highlights include:
- VIVO played a fundamental role in identifying the VT origin within the scar
- VIVO provided a more precise location than traditional 12-lead ECG methods
- After a 4-month follow-up, the patient reported no new episodes of VT or heart failure
CEO David Jenkins emphasized the potential of VIVO as a non-invasive, patient-specific, pre-procedural planning tool for improving procedural outcomes in non-invasive ablation treatments.
Catheter Precision, Inc. (NYSE American:VTAK) ha annunciato una nuova pubblicazione nel numero di ottobre 2024 di HeartRhythm Case Reports, evidenziando l'uso della loro tecnologia VIVO in una tecnica di ablazione nuova e non invasiva chiamata radioablazione stereotattica (STAR). La procedura, che utilizza fasci di fotoni esterni per mirare e ablare aree del cuore responsabili di aritmie, ha mostrato successo in un paziente non reattivo all'ablazione tradizionale per tachicardia ventricolare.
I punti salienti includono:
- VIVO ha giocato un ruolo fondamentale nell'identificazione dell'origine della tachicardia ventricolare all'interno della cicatrice
- VIVO ha fornito una posizione più precisa rispetto ai metodi tradizionali dell'ECG a 12 derivazioni
- Dopo un follow-up di 4 mesi, il paziente ha segnalato nessun nuovo episodio di tachicardia ventricolare o insufficienza cardiaca
Il CEO David Jenkins ha sottolineato il potenziale di VIVO come strumento di pianificazione pre-operatoria specifico per il paziente e non invasivo, per migliorare i risultati procedurali nei trattamenti di ablazione non invasiva.
Catheter Precision, Inc. (NYSE American:VTAK) ha anunciado una nueva publicación en el número de octubre de 2024 de HeartRhythm Case Reports, destacando el uso de su tecnología VIVO en una técnica de ablación novedosa y no invasiva llamada radioablación estereotáctica (STAR). El procedimiento, que utiliza haces de fotones externos para atacar y ablacionar áreas del corazón responsables de arritmias, mostró éxito en un paciente que no respondió a la ablación tradicional para taquicardia ventricular.
Los puntos clave incluyen:
- VIVO jugó un papel fundamental en la identificación del origen de la taquicardia ventricular dentro de la cicatriz
- VIVO proporcionó una localización más precisa que los métodos tradicionales de ECG de 12 derivaciones
- Después de un seguimiento de 4 meses, el paciente reportó no haber tenido nuevos episodios de taquicardia ventricular ni insuficiencia cardíaca
El CEO David Jenkins enfatizó el potencial de VIVO como una herramienta de planificación preoperatoria específica para el paciente y no invasiva, para mejorar los resultados del procedimiento en tratamientos de ablación no invasiva.
캐더터 프리시전, Inc. (NYSE American:VTAK)는 2024년 10월 HeartRhythm Case Reports에 그들의 VIVO 기술를 사용한 신규 비침습적 절차인 입체 방사선 절제술 (STAR)에 대한 새로운 출판물을 발표했습니다. 이 절차는 외부 광선 빔을 사용하여 심장 내 부정맥을 유발하는 부위를 표적으로 삼고 제거하며, 기존의 심실 빈맥을 위한 전통적인 절제술에 반응하지 않는 환자에서 성공을 보였습니다.
주요 내용은 다음과 같습니다:
- VIVO는 흉터 내에서 VT의 기원을 식별하는 데 중요한 역할을 했습니다
- VIVO는 기존의 12유도 ECG 방법보다 더 정밀한 위치를 제공했습니다
- 4개월 후 추적 조사에서 환자는 VT 또는 심부전의 새로운 에피소드를 보고하지 않았습니다
CEO 데이비드 젠킨스는 VIVO가 비침습적이며 환자 맞춤형의 시술 전 계획 도구로서 비침습적 절제술의 시술 결과 개선에 기여할 가능성을 강조했습니다.
Catheter Precision, Inc. (NYSE American:VTAK) a annoncé une nouvelle publication dans le numéro d'octobre 2024 de HeartRhythm Case Reports, mettant en lumière l'utilisation de leur technologie VIVO dans une nouvelle technique d'ablation non invasive appelée radioablation stéréotaxique (STAR). La procédure, qui utilise des faisceaux de photons externes pour cibler et ablater des zones du cœur responsables des arythmies, a montré un succès chez un patient non réactif à l'ablation traditionnelle pour tachycardie ventriculaire.
Les points clés incluent :
- VIVO a joué un rôle fondamental dans l'identification de l'origine de la tachycardie ventriculaire au sein de la cicatrice
- VIVO a fourni une localisation plus précise que les méthodes ECG traditionnelles à 12 dérivations
- Après un suivi de 4 mois, le patient n'a signalé aucun nouvel épisode de tachycardie ventriculaire ou d'insuffisance cardiaque
Le PDG David Jenkins a souligné le potentiel de VIVO en tant qu'outil de planification pré-procédurale spécifique au patient et non invasif, pour améliorer les résultats procéduraux dans les traitements d'ablation non invasive.
Catheter Precision, Inc. (NYSE American:VTAK) hat eine neue Veröffentlichung in der Oktoberausgabe 2024 von HeartRhythm Case Reports angekündigt, die die Anwendung ihrer VIVO-Technologie in einer neuartigen, nicht-invasiven Ablationstechnik namens stereotaktische Radioablation (STAR) hervorhebt. Das Verfahren, das externe Photonenstrahlen verwendet, um Bereiche des Herzens zu zielen und abzulatieren, die für Arrhythmien verantwortlich sind, zeigte Erfolge bei einem Patienten, der auf traditionelle Ablation bei ventrikulärer Tachykardie nicht ansprach.
Wichtige Highlights sind:
- VIVO spielte eine fundamentale Rolle bei der Identifizierung des Ursprungs der VT innerhalb der Narbe
- VIVO lieferte einen genaueren Standort als traditionelle 12-Kanal-EKG-Methoden
- Nach einer 4-monatigen Nachsorge berichtete der Patient von keinen neuen Episoden von VT oder Herzinsuffizienz
CEO David Jenkins betonte das Potenzial von VIVO als nicht-invasive, patientenspezifische Planungswerkzeug zur Verbesserung der Verfahrens Ergebnisse bei nicht-invasiven Ablationstherapien.
- VIVO technology demonstrated superior precision in identifying VT origin compared to traditional methods
- Successful patient outcome with no new episodes of VT or heart failure after 4 months
- Potential for VIVO to become an essential tool in non-invasive ablation procedures
- Non-invasive ablation technique (STAR) is still in its infancy and only available to a small group of patients
- STAR treatment is not yet approved for broader use
Insights
This publication highlights a significant advancement in cardiac arrhythmia treatment, specifically for ventricular tachycardia (VT). The use of Catheter Precision's VIVO system in conjunction with stereotactic radioablation (STAR) represents a novel non-invasive approach that could potentially revolutionize treatment for patients who have not responded to traditional ablation methods.
Key points of impact:
- VIVO's role in precisely identifying VT origin within scar tissue, outperforming traditional 12-lead ECG methods
- Successful patient outcome after 4 months, with no VT recurrence or heart failure episodes
- Potential for VIVO to become an essential tool in the growing field of non-invasive cardiac ablation
While STAR is still in its early stages and not widely available, this clinical publication provides proof of concept for Catheter Precision's technology. If STAR gains broader approval, VIVO could see increased adoption, potentially driving future revenue growth for VTAK. However, investors should note that widespread implementation may take time and regulatory hurdles could impact the timeline for broader market penetration.
This clinical publication represents a positive development for Catheter Precision (VTAK), but its immediate financial impact is likely Key financial considerations include:
- Market Potential: The successful use of VIVO in this novel procedure could expand its addressable market, particularly if STAR becomes more widely adopted.
- Competitive Advantage: VIVO's superior performance in identifying VT origin compared to traditional methods may strengthen its market position.
- Revenue Growth: While promising, the financial impact will depend on the rate of STAR adoption and VIVO's integration into these procedures.
- R&D Investment: Continued development and refinement of VIVO for non-invasive applications may require additional R&D spending.
Given VTAK's small market cap of
FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024 issue of HeartRhythm Case Reports.
This recent publication focuses on a patient procedure in which a novel, non-invasive ablation technique known as stereotactic radioablation ("STAR") was used. STAR utilizes external photon beams, similar to those used to treat cancer, to non-invasively target and ablate areas of the heart responsible for the arrhythmia. Though new, and not widely available, this technique has proven to have success in patients that have not responded to traditional ablation for ventricular tachycardia. For non-invasive ablation to be successful, pre-procedural information is required to define the target location for ablation. VIVO can provide such information and during this procedure VIVO was able to identify a more precise location than traditional methods alone. Highlights from this procedure include:
VIVO was a valuable tool that played a fundamental role in identifying the VT origin within the scar.
The 12-lead ECG by itself suggested a less clear location than that designated by VIVO. Precise target delineation is pivotal for the decision to not only treat the patient with STAR, but crucial for success of the treatment.
After a 4-month follow-up, the patient is asymptomatic without acute adverse events or new episodes of ventricular tachycardia (VT) or heart failure (HF).
David Jenkins, CEO of Catheter Precision said, "VIVO uses proprietary algorithms for 3D electrical modeling of the heart. This procedure highlights the benefits of combining traditional ECGs with 3D imaging (such as CTs or MRIs) and the VIVO technology to create a patient specific solution. Non-invasive ablation is still in its infancy and currently only available to a small group of patients. However, the treatment is promising and essentially requires VIVO, a non-invasive, patient specific, pre-procedural planning tool, to be confident in a successful outcome. If the treatment option becomes available and approved for broader use, we believe our patented and proprietary product, VIVO, will be an important asset to procedural outcomes to improve patient lives."
About HeartRhythm Case Reports
HeartRhythm Case Reports provides rapid online electronic publication of the most important current case reports, illustrations, and educational vignettes in the field of cardiac arrhythmias and electrophysiology. The Journal publishes case reports and series devoted to the diagnosis and treatment of heart rhythm disorders, as well as the electrophysiology of the heart and blood vessels. All articles are peer-reviewed and the Journal is published online only with open access.
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
VIVO Indications for Use (USA)
VIVO is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.
VIVO is intended to be used as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
SOURCE: Catheter Precision, Inc.
View the original press release on accesswire.com
FAQ
What is the new clinical publication about Catheter Precision's VIVO technology?
How did VIVO (VTAK) perform in the clinical case study?
What were the patient outcomes in the VIVO-assisted STAR procedure?
What is the current availability of the STAR treatment using VIVO (VTAK)?
